Previously, CSC+ cells were reported to exhibit greater immune tolerance (e.g., CD271+ human melanoma cells [29]) and higher secretion of growth factors (e.g., CD133+ human glioblastoma cells [47]) than CSC− cells. The gene discussed is PROM1; the disease is glioblastoma.